Literature DB >> 12033599

Controlled release of rhodium (II) carboxylates and their association complexes with cyclodextrins from hydroxyapatite matrix.

A E Burgos1, J C Belchior, R D Sinisterra.   

Abstract

Preparation and characterization of a controlled release system of rhodium (II) citrate, acetate. propionate, butyrate and their inclusion or association compounds with cyclodextrin (CD) are described. The porous hydroxyapatite (HA) was characterized by X-ray powder pattern diffraction, FTIR and solid state 31P NMR. Scanning electron microscopy and gas adsorption analysis (BET) were also performed. Release profiles of rhodium (II) carboxylates and their inclusion or association compounds from HA matrix were obtained at different drug loadings (5% and 10%). These were reasonably consistent with a diffusion model. This analysis, mainly using rhodium (II) citrate and butyrate, showed that the strategy of using CDs with a HA matrix may offer a useful new method for the controlled release of these compounds, and hence an alternative strategy for the controlled release of chemotherapeutic agents containing toxic metals. This may be a valuable new technique for localized anti-tumour chemotherapy that minimizes the side effects of such agents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12033599     DOI: 10.1016/s0142-9612(01)00386-6

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  7 in total

1.  Development of porous HAp and β-TCP scaffolds by starch consolidation with foaming method and drug-chitosan bilayered scaffold based drug delivery system.

Authors:  B Kundu; A Lemos; C Soundrapandian; P S Sen; S Datta; J M F Ferreira; D Basu
Journal:  J Mater Sci Mater Med       Date:  2010-07-20       Impact factor: 3.896

2.  Macro-to-micro porous special bioactive glass and ceftriaxone-sulbactam composite drug delivery system for treatment of chronic osteomyelitis: an investigation through in vitro and in vivo animal trial.

Authors:  Biswanath Kundu; Samit Kumar Nandi; Sudip Dasgupta; Someswar Datta; Prasenjit Mukherjee; Subhasis Roy; Aruna Kumari Singh; Tapan Kumar Mandal; Partha Das; Rupnarayan Bhattacharya; Debabrata Basu
Journal:  J Mater Sci Mater Med       Date:  2011-01-08       Impact factor: 3.896

3.  Development of new localized drug delivery system based on ceftriaxone-sulbactam composite drug impregnated porous hydroxyapatite: a systematic approach for in vitro and in vivo animal trial.

Authors:  Biswanath Kundu; Chidambaram Soundrapandian; Samit K Nandi; Prasenjit Mukherjee; Nandadulal Dandapat; Subhasis Roy; Bakul K Datta; Tapan K Mandal; Debabrata Basu; Rupnarayan N Bhattacharya
Journal:  Pharm Res       Date:  2010-05-13       Impact factor: 4.200

Review 4.  Cyclodextrins in drug delivery: an updated review.

Authors:  Rajeswari Challa; Alka Ahuja; Javed Ali; R K Khar
Journal:  AAPS PharmSciTech       Date:  2005-10-14       Impact factor: 3.246

5.  Free Rhodium (II) citrate and rhodium (II) citrate magnetic carriers as potential strategies for breast cancer therapy.

Authors:  Marcella L B Carneiro; Eloiza S Nunes; Raphael C A Peixoto; Ricardo G S Oliveira; Luiza H M Lourenço; Izabel C R da Silva; Andreza R Simioni; Antônio C Tedesco; Aparecido R de Souza; Zulmira G M Lacava; Sônia N Báo
Journal:  J Nanobiotechnology       Date:  2011-03-28       Impact factor: 10.435

6.  Nickel, palladium and rhodium induced IFN-gamma and IL-10 production as assessed by in vitro ELISpot-analysis in contact dermatitis patients.

Authors:  Valentina Bordignon; Francesca Palamara; Paola Cordiali-Fei; Antonella Vento; Arianna Aiello; Mauro Picardo; Fabrizio Ensoli; Antonio Cristaudo
Journal:  BMC Immunol       Date:  2008-05-15       Impact factor: 3.615

7.  Effect of Polymers on the Physicochemical Properties and Biological Performance of Fenoprofen Calcium Dihydrate-Triacetyl-β-Cyclodextrin Complex.

Authors:  Hussein O Ammar; Tarek S Makram; Shaimaa Mosallam
Journal:  Pharmaceutics       Date:  2017-07-03       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.